Eric J. Small

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (43)

Year:

2026

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Hierarchical clustering analyses of benign, localized, and mCRPC tumors representing the expression of neuroendocrine marker genes (NE), androgen-related genes (AR), and genes related to squamous (SQUAM) differentiation

Year:

2025

Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.

Year:

2025

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.

Year:

2025

Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.

Year:

2025

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.

Year:

2025

Purpose: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts. Thus, we sought to identify the intrinsic molecular subtypes of mCRPC and assess molecular and clinical correlates in the largest combined cohort of mCRPC samples with gene expression data available to date. Experimental Design: We combined and batch-effect corrected gene expression data from four mCRPC cohorts from the Fred Hutchinson Cancer Research Center ( N = 157), a small-cell neuroendocrine (NE) prostate cancer (SCNC)–enriched cohort from Weill Cornell Medicine ( N = 49), and cohorts from the Stand Up 2 Cancer/Prostate Cancer Foundation East Coast Dream Team ( N = 266) and the West Coast Dream Team ( N = 162). Results: Hierarchical clustering of RNA-sequencing data from these 634 mCRPC samples identified two distinct adenocarcinoma subtypes, one of which (adeno-immune) was characterized by higher gene expression of immune pathways, higher CIBERSORTx immune scores, diminished ASI benefit, and non–lymph node metastasis tropism compared with an adeno-classic subtype. We also identified two distinct subtypes with enrichment for an NE phenotype, including an NE-liver subgroup characterized by liver metastasis tropism, PTEN loss, and APC and SPOP mutations compared with an NE-classic subgroup. Conclusions: Our results emphasize the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, and suggest that future studies should consider incorporating transcriptome-wide profiling to better understand how these differences impact treatment responses and outcomes.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (33)

Meng Zhang

Assistant Professor of Urology

Emory University

UNITED STATES
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Joshua Lang

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Michelle R. Arkin

Professor and Department Chair

University of California

UNITED STATES
View details

Jiaoti Huang

Professor and Chairman

Duke Medicine

UNITED STATES
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Matthew Rettig

Professor

University of California, Los Angeles

UNITED STATES
View details

Shuang G. Zhao

University of Wisconsin-Madison

UNITED STATES
View details

Li Zhang

Professor

UCSF

UNITED STATES
View details

Emily Chan

Stanford University

UNITED STATES
View details

Kim Chi

Chief Medical Officer

BC Cancer

CANADA
View details

Lixing Yang

University of Chicago

UNITED STATES
View details

Michelle Badura

Lecturer

Santa Clara University

UNITED STATES
View details

Raunak Shrestha

Assistant Professor

Uniformed Services University of the Health Sciences

UNITED STATES
View details

Fred Saad

Université de Montréal

CANADA
View details

Tomasz Michal Beer

Oregon Health & Science University

UNITED STATES
View details

Emily Egusa

University of California, San Francisco

UNITED STATES
View details

Anil Parsram Bidkar

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Lawrence Fong

Fred Hutch Cancer Center

UNITED STATES
View details

Owen Witte

University Professor

University of California, Los Angeles

UNITED STATES
View details

Brandon Chen

University of California, San Francisco

UNITED STATES
View details

Arian Lundberg

Assistant Professor at KTH Royal Institute of Technology

KTH Royal Institute of Technology

SWEDEN
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

sinan wang

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Christopher Evans

Professor

University of California, Davis

UNITED STATES
View details

Robert R. Flavell

University of California

UNITED STATES
View details

Minkyu Kim

University of California

UNITED STATES
View details

Mathieu Lupien

Senior Scientist

University Health Network

CANADA
View details

Rahul Aggarwal

University of California

UNITED STATES
View details

Terence Friedlander

University of California, San Francisco

UNITED STATES
View details